HK inno.N said it has signed a contract manufacturing agreement (CMO) with Brexogen, a company specializing in exosome therapeutics, to produce cell lines for exosome therapeutics derived from stem cells.

The agreement follows a memorandum of understanding signed between the two companies in April.

Under the accord, inno.N will produce cell lines for myocardial infarction and non-alcoholic steatohepatitis (NASH) therapeutics being developed by Brexogen.

However, HK inno.N did not unveil the amount of the contract and the scale of production, citing contractual reasons.

Cell line production will be carried out at HK Inno. N's Cell and Gene Treatment Center in Hanam, Gyeonggi Province.

Once HK inno.N produces the cell lines, Brexogen will extract nanoparticles, or exosomes, from the cell lines and utilize them in the nonclinical and clinical development of its drug candidates BRE-MI01 (myocardial infarction) and BRE-NA01 (NASH).

"In addition to this CMO contract, we will create various collaborations utilizing our Cell and Gene Treatment Center," HK inno.N Bio Research Center Executive Director Won Sung-yong, said.

Brexogen CEO Kim Sue also said, "Starting with this CMO agreement, we look forward to continuing our development collaboration on various exosome therapeutic pipelines discovered by Brexogen's BG-Platform."